Inclisiran Safe, Effective in Dyslipidemia, ASCVD Regardless of BMI
Using ORION 9, 10, and 11 data, investigators assessed inclisiran in patients with heterozygous familial hypercholesterolemia, ASCVD, or ASCVD risk.
LDL-C
Preterm Delivery May Increase Chronic Hypertension Risk in Women
Risk for hypertension increased within first 10 years after delivery and remained elevated at least 40 years later/
Maternal Cholesterol in Pregnancy Tied to AMI Severity in Adult Offspring
Increased maternal cholesterol levels during pregnancy linked to greater severity of acute myocardial infarction in adult offspring.
Metabolic Syndrome Linked to Increased Risk for Stroke Recurrence
Low levels of HDL cholesterol and having two or more components of metabolic syndrome predict recurrence
Assessing HDL Anti Inflammatory Capacity Aids CV Risk Prediction
HDL anti-inflammatory capacity associated with cardiovascular disease events independent of cholesterol efflux capacity
High Intake of Cholesterol Associated with Higher Mortality
Increased mortality associated with egg consumption largely influenced by cholesterol intake.
Total Cholesterol May Influence Cardiovascular Risk in Patients With Migraine
A team of researchers conducted a systematic review to examine the association between migraine and lipid profile differences.
Evkeeza Approved for Homozygous Familial Hypercholesterolemia
The approval was based on data from the double-blind, placebo-controlled phase 3 ELIPSE HoFH trial.
Addition of Evolocumab to Statin Therapy Found to Lower Risk for Complex Coronary Disease Requiring Revascularization
Addition of evolocumab to statin therapy was found to lower the risk for complex coronary disease requiring revascularization.
Clinical Benefits of Lipid-Lowering Therapy in CAD With vs Without Familial Hypercholesterolemia
Patients with familial hypercholesterolemia were found to get more clinical benefits than those with CAD for comparable reductions in LDL-c.
- Loading...
Loading...
Next post in Dyslipidemia
Loading... 
Loading...